<i>LRP1b</i> Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial
LRP1b mutations are a candidate predictive biomarker for immune checkpoint inhibition versus chemotherapy in NSCLC. Further mechanistic characterization of LRP1b and prospective validation are warranted and might enable future clinical use.
Authors
- Virginia Ip (ORCID: https://orcid.org/0009-0001-1448-6633)
- Ryon P. Graf (ORCID: https://orcid.org/0000-0002-8065-4148)
- Chunzhe Duan (ORCID: https://orcid.org/0009-0008-5368-3198)
- Andrew J. Armstrong (ORCID: https://orcid.org/0000-0001-7012-1754)
- Gerald Li (ORCID: https://orcid.org/0000-0002-5617-6262)
- David Balli (ORCID: https://orcid.org/0009-0000-9877-9347)
- Yu-Han Hung (ORCID: https://orcid.org/0000-0002-3278-3201)
- Neal Ready
- Hilary Dietz (ORCID: https://orcid.org/0000-0001-9586-9902)
- William J. Geese (ORCID: https://orcid.org/0009-0006-9371-5487)
Institutions
- Duke University (US)
- GlobalFoundries (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Duke Medical Center (US)
- Bristol-Myers Squibb (Sweden) (SE)
- Veterans Medical Research Foundation of San Diego (US)
- Foundation Medicine (United States)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-0952
- Citations
- 1
- Primary Topic
- Genetic factors in colorectal cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.47